SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."

Business Wire India

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo’s Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312457783/en/

SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."

The Ginza flagship, located in a prime area near GINZA SIX, will feature dedicated VIP rooms for executive clientele and the growing number of international patients, strengthening the brand’s global presence. Leveraging its robust network of 283 affiliated clinics (as of December 2025) and extensive clinical data, SBC Medical continues to advance its multi-branding strategy to meet evolving market needs.

Following the successful validation of the business model at the Ebisu clinic launched in April 2025, the new flagship in Ginza is expected to further diversify the Group’s revenue base and improve profitability through a high-value-added service model.

The aesthetic healthcare sector is undergoing rapid evolution, driven by the continuous development of new treatment devices and formulations, which is increasing consumer awareness and demand. Modern patients are increasingly seeking the latest technology, applying the same level of discernment to high-end cosmetics. To address these market dynamics, NEO Skin Clinic leverages the Company’s extensive global network and strong relationships with medical device manufacturers to maintain a premier lineup of treatments that are regularly updated. The brand offers a sustainable, accessible pricing structure aligned with international standards, including those in South Korea, to meet rising patient expectations for both quality and value.

Beyond advanced technology, NEO Skin Clinic emphasizes a proprietary treatment approach that combines scientific precision with objective data from the VISIA skin diagnostic system. To ensure technical excellence, the brand has appointed Dr. Nariaki Miyata, a leading authority on aesthetic dermatology in Japan, and Dr. Youn Seongjae, Representative Director of Leaders Dermatology Clinic in South Korea, as technical advisors. By integrating advanced clinical insights from both Japan and South Korea, SBC Medical has established a world-class training system for its physicians and staff.

As global interest in non-invasive treatments and quality of life continues to grow, SBC Medical remains committed to maintaining its domestic dominance and pursuing international expansion.

The Company plans to further expand its footprint into the Nagoya and Kobe areas by the end of 2026, aiming for sustainable growth and long-term enhancement of corporate value.

Message from Soichiro Morikawa, M.D., Director

I believe that the essence of aesthetic healthcare lies not merely in the 'procedure' itself, but in the precision of 'diagnosis' and 'treatment' that dictates the final outcome. Every customer is unique—skin condition, fat distribution, muscle movement, and the progression of aging vary from person to person. At NEO Skin Clinic Ginza, I place the highest priority on designing treatment strategies based on rigorous medical evidence, taking into account both the customer’s current state and future physiological changes. Whether using injectable therapies or advanced energy-based devices, achieving natural and sustainable results requires a deep understanding of each modality’s characteristics, applied at the optimal timing and in the right combination. My commitment is to provide aesthetic dermatology that moves beyond subjective intuition, focusing instead on evidence-based care to ensure long-term beauty and facial harmony.

Clinic Overview

Business Hours: 10:00 AM – 7:00 PM
Regularly Closed: Mondays and Thursdays
Location: 3F, Hulic Ginza Wall Building, 6-13-16 Ginza, Chuo-ku, Tokyo 104-0061, Japan
Access:
2-minute walk from Exit A1 of Higashi-ginza Station (Tokyo Metro Hibiya Line)
3-minute walk from Exit A5 of Ginza Station (Tokyo Metro Ginza and Hibiya Lines)
Phone: 0120-217-498 (Toll-free within Japan)
Official Website: https://www.sbc-neoskinclinic.jp/

About SBC Medical Group Holdings Incorporated

SBC Medical Group Holdings Incorporated is a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com

For more insights and updates from SBC Holdings, follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.